

Portugal

MOST INNOVATIVE BIOTECHNOLOGY COMPANY

SICGEN Antibodies

www.sicgen.masterinsoft.com | + 351 919 145 219 | information@sicgen.pt



Based in Coimbra, SICGEN Antibodies is a biotechnology company specialising in the development and production of polyclonal antibodies. SICGEN uses cutting-edge technology to develop a product of the highest quality, which makes huge contributions towards research into life sciences. The company's facility houses an advanced lab space, and an animal house comprising of domestic goats. These animals are tested for specific pathogens on a quarterly basis, by expert veterinarians, and SICGEN fully operates under the General Veterinary Directorate (DGV) and its guidelines regarding animal welfare.

Polyclonal antibodies hold a variety of advantages over its monoclonal counterparts, including multiple epitopes, quicker production times, and competitiveness. Used as either a primary or secondary antibody, polyclonal varieties are open to a range of possibilities and techniques, such as Enzyme-linked Immunosorbent Assay (ELISA), Fluorescence-activated Cell Sorting (FACS), and Immunofluorescence Assay (IF). SICGEN provides a full service at highly-competitive prices, including cDNA sourcing and affinity purified antibody production. The innovative antibody packages are customised to the client's requirements, but can include the antigen's designs, synthesis, and conjugation. Furthermore, immunisation, the ELISA test, purification, and antibody labelling are also offered. SICGEN's knowledgeable staff include certified researchers, technicians and veterinarians, who are consistently supported in furthering their education and skillset.



SICGEN USES CUTTING-EDGE TECHNOLOGY TO DEVELOP A PRODUCT OF THE HIGHEST QUALITY, WHICH MAKES HUGE CONTRIBUTIONS TOWARDS RESEARCH INTO LIFE SCIENCES.



The judging panel was impressed by the response to the COVID-19 pandemic. SICGEN Antibodies was able to produce a range of antibodies used by international scientific bodies to improve and accelerate the important research into the SARS-CoV-2 strain. The company's clients come in the form of various institutions around the globe, including major universities, research institutions, pharmaceutical manufacturers, and biotechnology companies, and SICGEN's main markets are North America, Europe, and the Far East. As a business, it continues to innovate and develop its research, extending its product line. By 2020, SICGEN had almost 300 different products available, most of which are antibodies, and some have even been recognised in prestigious scientific research publications such as Nature, Cell and Science.